An analysis in the Journal of the American College of Cardiology shows that renal denervation is a cost-effective treatment for high blood pressure, more good news out of Medtronic’s Symplicity renal denervation trial. Medtronic’s Symplicity renal denervation system for high blood pressure An analysis of data from Medtronic’s (NYSE:MDT) Symplicity HTN 2 renal denervation trial showed that the procedure is a cost-effective way to treat resistant hypertension, or high blood pressure. It’s more good news for the Fridley, Minn.-based medical device monolith, which is still riding high on strong results for the technology released at the recent annual meeting of the American College of Cardiology.
